X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

CRISPR and Vertex treat first patient in gene-editing therapy trial

Content Team by Content Team
28th February 2019
in Clinical Trials, Manufacturing, News
CRISPR and Vertex treat first patient in gene-editing therapy trial

Swiss gene editing company CRISPR Therapeutics and US-based Vertex Pharmaceuticals have started treating patients in a Phase I/II clinical trial of an investigational gene-editing therapy CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT).

CTX001 is an autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being developed to help patients suffering from severe hemoglobinopathies.

The product is the first therapy under a research collaboration formed by CRISPR and Vertex in 2015 to use CRISPR/Cas9 for developing new treatments targeting underlying genetic causes of disease.

CTX001’s safety and efficacy will be assessed in patients aged 18-35 years with TDT, non-beta zero / beta zero subtypes as part of the open-label Phase I/II trial.

The trial will initially involve sequential treatment of two patients and will be opened for further concurrent enrolment based on the data obtained. It will take place at clinical sites across Canada and Europe.

A Phase I/II trial will also be conducted in the US and also include beta thalassemia patients.

CRISPR Therapeutics CEO Samarth Kulkarni said: “We have made tremendous progress with CTX001 and are pleased to announce that we’ve treated the first patient with beta thalassemia in this clinical study.

“Treating the first patient in this study marks an important scientific and medical milestone and the beginning of our efforts to fully realise the promise of CRISPR/Cas9 therapies as a new class of potentially transformative medicines to treat serious diseases.”

CTX001 is also being studied in a separate Phase I/II trial for severe sickle cell disease (SCD). This trial has commenced enrolment and treatment is expected to be initiated this year.

The trial will also assess the safety and efficacy of the product in severe SCD patients aged 18-35 years. Its design includes the initial treatment of two patients, followed by broader concurrent enrolment.

The trial is being conducted in the US, with plans to expand to Canada and Europe over the coming months.

During the trials, hematopoietic stem cells will be collected from peripheral blood, edited using the CRISPR/Cas9 technology and infused back into the patient via a stem cell transplant.

Patients will be monitored to establish when the edited cells start production of mature blood cells, as well as to assess the impact of CTX001 on various disease measures.

Previous Post

PPD and HLT to Create Data Science-Driven Clinical Research Solutions in China to Enhance Global Drug Development

Next Post

ACG expands its footprint in Brazil

Related Posts

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Next Post
ACG expands its footprint in Brazil

ACG expands its footprint in Brazil

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In